Positioned as Australia’s leading group in the global medical cannabis sector

  • Positioned as Australia’s leading group in the global medical cannabis sector
  • Shaping the future of medicinal cannabis
  • A strong team with relevant and complementary skill-sets, experiences and networks
See More

When consumed, Cannabinoids bind to receptor sites in the brain & body mimicking the naturally occurring Endocannabinoids produced in human bodies.

For over 12,000 years the Cannabis plant has provided humankind with food, fibre and medicine.

Hundreds of clinical studies and significant first hand evidence are demonstrating the medical benefits of this ancient traditional medicine.

We believe Australian patients have the right to access high quality, cost effective, cannabinoid medicines.

Quality Control is Our No.1 Priority

Ensuring 'Good Manufacturing Practices', we are committed to supplying our clients with a consistent & reliable source of high-quality medicinal cannabis.

AusCann brings together a strong team with relevant & complementary skill-sets, experience and networks.

Key People

Dr Mal Washer

Chairman MBBS, ex Member of the House of Representatives

Dr Washer was a Liberal member of the Australian House of Representatives from 1998 to 2013. He was educated at the University of Western Australia, graduating in 1970 with degrees in medicine and surgery. He was a general practitioner before entering politics & established a number of prominent medical centres in Western Australia. Mal was also past chair of the Alcohol and Other Drugs Council of Australia. He has extensive experience in agricultural and horticultural activities and currently operates a commercial avocado plantation in Western Australia bringing highly relevant medical and horticultural expertise and experience to AusCann.

Elaine Darby

Managing Director BSc(Hons) LLB(Hons)

Elaine holds a Bachelor of Science in Biochemistry & Microbiology, Honours in Molecular Biology and a Bachelor of Laws. Previous roles have included as a lawyer with top tier corporate law firm Clayton Utz, Media and Communications Officer for an Australian Federal Member of Parliament, and Managing Director and Senior Winemaker of Aquila Estate Winery where she was an award winning wine-maker and also involved in international business development and marketing in territories including Singapore, Japan, Canada, the United Kingdom, and the United States.

Elaine is currently investment director of Biologica Ventures Pty Ltd which provides investment opportunities as well as project and clinical trial management for digital health and biotechnology companies.

Harry Karelis

Executive Director BSc(Hons) MBA Grad.Dip Applied Finance & Investment CFA FFin FAICD

Mr Karelis is the founder of Titan Capital Partners - a privately held investment group involved in a range of projects. He graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States.

Prior to establishing Titan, Mr Karelis worked in the financial services industry with roles in financial analysis and funds management both in Australia and overseas including extended periods at Hartley Poynton (now Hartleys) and Challenger Group. He has in excess of 23 years diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing. He has considerable cross-border experience and has acted as a Director on several public and private companies in Australia, Singapore, the United Kingdom and the United States of America.

Dr Stewart Washer

Consultant BSc(Hons) PhD

Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently the Chairman of Orthocell Ltd (ASX:OCC), a regenerative medicine company dedicated to providing innovative treatments for people suffering from tendon, cartilage and soft tissue injuries; Chairman of Cynata Therapeutics Ltd (ASX:CYP) who are developing stem cell therapies; and Chairman of Minomic International Ltd who have an accurate non-invasive test for prostate cancer.

Stewart was previously the CEO of Calzada Ltd (ASX:CZD), the founding CEO of Phylogica Ltd (ASX:PYC) and before this, he was CEO of Celentis and managed the commercialisation of intellectual property from AgResearch in New Zealand with 650 Scientists and $130m revenues. He was also a founder of a NZ$120m New Zealand based life science fund and Venture Partner with the Swiss based Inventages Nestlé Fund. He is currently Investment Director with Bioscience Managers.

Stewart has held a number of Board positions in the past as the Chairman of iSonea Ltd (ASX:ISN), Resonance Health Ltd (ASX:RHT) and Hatchtech Pty Ltd, a Director of iCeutica Pty Ltd, Immuron Ltd (ASX:IMC) and AusBiotech Ltd. He was also a Senator with Murdoch University and is currently the Chairman of Firefly Health.

Dr Alex Wodak AM

Medical Advisory Board

Dr Wodak is a physician and the director of the Alcohol and Drug Service, at St Vincent’s Hospital in Sydney, Australia. He is a notable advocate of drug reform laws and helped establish the National Drug and Alcohol Research Centre, the NSW Users AIDS Association, and the Australian Society of HIV Medicine. Wodak is President of the Australian Drug Law Reform Foundation and was President of the International Harm Reduction Association.

Cheryl Edwardes

Independent Non-Executive Director LLM, BA, GAICD

Cheryl was the former Attorney-General for Western Australia and Minister for the Environment. Cheryl was most recently Executive General Manager for External Affairs, Government Relations and Approvals at Hancock Prospecting-a company associated with one of Australia’s wealthiest individuals.

Cheryl has extensive experience of successful negotiations to ensure that critical primary agreements and government approvals are obtained in a timely fashion. Such agreements and approvals include the Roy Hill Rail State Agreement and the Special Railway Licence; Port Lease and Licence; Native Title Agreements; Environmental Approvals, State and Federal; and many other critical approvals for Hancock Prospecting Pty Ltd and Roy Hill Iron Ore and Infrastructure.

Mr Bruce Linton

Non-Executive Director BPA

Mr Bruce Linton is the founder, Chairman and CEO of Canopy Growth Corporation, one of the world’s leading medical cannabis companies. Canopy Growth, through its subsidiaries Tweed and Bedrocan Canada, is the world’s largest producer of legal cannabis, and recently entered into a strategic partnership with AusCann.

Bruce has more than ten years of senior executive experience in the high-tech sector as a founder, executive and board member.  He has a proven track record of international success, working extensively with the World Bank and the Asia Development Bank. Bruce enjoys a high profile in the global medicinal cannabis sector and has a demonstrable track record of raising the capital required to build large scale cannabis business.

Bruce McHarrie

Non-Executive Director BCom FCA GAICD

Bruce is a highly experienced senior executive and independent company director with a background in the life sciences industry focussed on finance, operations, business and investment management and strategic planning.

In addition to AusCann, Bruce is a non-executive director of Adherium Limited, an ASX-listed digital health technologies company; he is Chairman of the Animal Ethics Committee of the child health research organisation, Telethon Kids Institute, and undertakes corporate consulting activities.

Bruce previously served as the Chief Financial Officer, Director of Operations and Director of Strategic Projects with the Telethon Kids Institute in Western Australia. Prior to joining the Institute, Bruce was based in London as an Assistant Director at Rothschild Asset Management in the Bioscience Unit, a life sciences private equity group investing in early stage biotechnology, healthcare and agribusiness companies. He co-founded two Institute spin-outs including publicly listed drug discovery company, Phylogica Limited, and has held a number of other non-executive director positions in biotechnology and not-for-profit healthcare organisations.

He is a Fellow of the Institute of Chartered Accountants Australia and New Zealand, holds a Bachelor of Commerce degree from the University of Western Australia, and is a graduate member of the Australian Institute of Company Directors.

Ms Susan Hunter

Company Secretary BCom, ACA, F Fin (GDipAFin(SecInst)), MAICD(Dip), ACIS(Dip)

Susan has over 20 years’ experience in the corporate finance industry. She is founder and managing director of consulting firm Hunter Corporate Pty Ltd, which specialises in the provision of corporate governance and company secretarial advice to ASX listed companies, and has previously held senior management roles at Ernst & Young, PricewaterhouseCoopers and Bankwest, both in Perth and Sydney.

Susan holds a Bachelor of Commerce, is a Member of the Australian Institute of Chartered Accountants, a Fellow of the Financial Services Institute of Australasia, a Graduate Member of the Australian Institute of Company Directors and an Associate of the Governance Institute of Australia Ltd. 

She is currently company secretary for several ASX listed companies.

Mr Troy Williams

Chief Financial Officer BBus, Grad Dip ACG, FGIA, FCIS, AIPA, ACFE

Troy has strong experience in management consulting, providing services in corporate governance, management and as a corporate accountant to both large and small to medium enterprises. He has a track record in delivering financial results and has 30 years’ experience in dealing with a range of stakeholders.

Troy is a Director of the Aboriginal Family Law Service and Deputy Chair of the Western Australia State Council at Governance Institute of Australia.

Dr Melinda Thompson

Assurance Manager BSc(Hon), PhD

Melinda holds a doctorate in biochemistry with postdoctoral research experience in molecular biology. She has over ten years’ experience, and has held several senior roles, in research and development management, with a focus on governance frameworks and operational processes, including the development of bespoke research management systems, contractual frameworks and risk assessment of research activities, including clinical trials.

Why Medicinal Cannabis

For over 12,000 years, the Cannabis plant has provided humankind with food, fibre, and medicine.

Global sentiment is changing

with an increasing number of jurisdictions legislating in favour of the use of Cannabis for medical purposes.

Numerous applications

include anti-convulsion, neuroprotectant, anti-inflammatory, anti-nausea, glaucoma, pain management & appetite stimulation are important areas.

Hundreds of clinical studies

and significant first hand evidence are demonstrating the medical benefits of this ancient traditional medicine.

Brief overview of medical cannabis

Cannabis is a flowering plant with evidence suggesting it has been used for medicinal purposes for millennia in cultures throughout the world as a curative for both mind and body.

Cannabinoids are a class of diverse chemical compounds secreted by Cannabis flowers, with at least 85 having been isolated, including the widely publicised Tetrahydrocannabinol (THC) and Cannabidiol (CBD).

When Cannabis is consumed, Cannabinoids bind to receptor sites in the brain & body (interacting with the Endocannabinoid System) mimicking the naturally occurring Endocannabinoids produced in the bodies of humans & animals.

Secreted in the same glands that produce Cannabinoids are around 200 Terpenes which give Cannabis its distinct and varying aromas. With the same Terpenes found in other plants occurring in Cannabis such as Linalool (Lavender), Caryophyllene (pepper & cloves), Limonene (citrus, rosemary, juniper, peppermint) and Myrcene (mango, lemongrass, thyme, hops). 

Medical cannabis can be delivered orally as a tincture or via oil-filled capsules, topically via skin creams and transdermal patches, infused into food products such as olive oil or vaporised for respiratory delivery.

Different Cannabinoids have different physiological effects depending on which receptors they bind to. For example, THC binds to receptors in the brain whereas CBD has a strong affinity for receptors located throughout the body. Different types of medical effects can be achieved through targeting different receptors using differing quantities of Cannabinoids (e.g. THC vs CBD).


Thank you for your interest, however we have no positions available at this time.